Durect logo

Durect share price today

(DRRX)

Durect share price is $0.77 & -₹0.77 as on 12 Dec 2024, 2.30 'hrs' IST

$0.77

-0.02

(-2.93%)

Market is closed - opens 8 PM, 12 Dec 2024

View live Durect share price in Dollar and Rupees. Guide to invest in Durect from India. Also see the sentimental analysis on Indian investors investing in Durect. Get details on the Indian mutual funds that are investing in Durect. Get Analyst recommendations and forecasts along with all the Durect's financials.

Durect share price movements

  • $0.77
    $0.82

    Day's Volatility :6.33%

  • $0.48
    $1.88

    52 Weeks Volatility :74.41%

Durect Returns

PeriodDurect CorpRussel 2000Index (Russel 2000)
3 Months
-49.94%
0.0%
0.0%
6 Months
-54.38%
0.0%
0.0%
1 Year
30.46%
0.0%
0.0%
3 Years
-92.13%
-20.0%
-20.0%

Durect Key Statistics

in dollars & INR

Previous Close
$0.7943
Open
$0.778
Today's High
$0.822
Today's Low
$0.77
Market Capitalization
$24.7M
Today's Volume
$213.9K
52 Week High
$1.88
52 Week Low
$0.481
Revenue TTM
$8.4M
EBITDA
$-24.9M
Earnings Per Share (EPS)
$-0.64
Profit Margin
-187.84%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-299.88%

How to invest in Durect from India?

It is very easy for Indian residents to invest directly in Durect from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Durect stock in both rupees (INR) and dollars (USD). Search for Durect or DRRX on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Durect or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Durect shares which would translate to -0.013 fractional shares of Durect as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Durect

46%

Period: Sep 12, 2024 to Dec 11, 2024. Change in 30 Days versus previous period

Search volume for Durect on INDmoney from India has grown in the last 30 days as on Dec 12, 2024. 46% more investors are searching Durect in the last 30 days versus the previous period.

Global Institutional Holdings in Durect

  • Ingalls & Snyder LLC

    6.39%

  • Richmond Brothers Inc

    3.68%

  • Vanguard Group Inc

    3.67%

  • Gagnon Securities LLC

    1.27%

  • Beirne Wealth Consulting Services, LLC

    1.21%

  • Geode Capital Management, LLC

    1.03%

Analyst Recommendation on Durect

Buy

    70%Buy

    30%Hold

    0%Sell

Based on 10 Wall street analysts offering stock ratings for Durect(by analysts ranked 0 to 5 stars)

Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
3
3
3
Sell
0
0
0

Analyst Forecast on Durect

What analysts predicted

Upside of 776.62%

Current:

$0.77

Target:

$6.75

Insights on Durect

  • Price Movement

    In the last 1 month, DRRX stock has moved down by -40.2%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 2.17M → 1.92M (in $), with an average decrease of 11.2% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -3.7M → -4.28M (in $), with an average decrease of 15.8% per quarter
  • DRRX vs CTLT (1 yr)

    In the last 1 year, Catalent, Inc. has given 69.5% return, outperforming this stock by 41.0%
  • DRRX vs NBIX (3 yr)

    In the last 3 years, Durect Corp has experienced a drawdown of -92.4%, however Neurocrine Biosciences Inc. resisted the overall trend and outperformed by 44.1%
  • Price to Sales

    ForDRRX every $1 of sales, investors are willing to pay $2.7, whereas for Catalent, Inc., the investors are paying $2.6 for every $1 of sales.

Durect Financials in INR & Dollars

FY18Y/Y Change
Revenue
$18.6M
↓ 62.25%
Net Income
$-25.3M
↑ 585.3%
Net Profit Margin
-136.4%
↓ 128.89%
FY19Y/Y Change
Revenue
$29.6M
↑ 59.25%
Net Income
$-22.8M
↓ 10.01%
Net Profit Margin
-77.08%
↑ 59.32%
FY20Y/Y Change
Revenue
$30.1M
↑ 1.85%
Net Income
$-2.5M
↓ 88.93%
Net Profit Margin
-8.38%
↑ 68.7%
FY21Y/Y Change
Revenue
$14.0M
↓ 53.58%
Net Income
$-38.1M
↑ 1411.7%
Net Profit Margin
-272.77%
↓ 264.39%
FY22Y/Y Change
Revenue
$19.3M
↑ 37.96%
Net Income
$-35.6M
↓ 6.66%
Net Profit Margin
-184.54%
↑ 88.23%
FY23Y/Y Change
Revenue
$8.5M
↓ 55.67%
Net Income
$-27.6M
↓ 22.37%
Net Profit Margin
-323.16%
↓ 138.62%
Q2 FY23Q/Q Change
Revenue
$2.1M
↑ 1.31%
Net Income
$-11.2M
↓ 8.55%
Net Profit Margin
-537.29%
↑ 57.94%
Q3 FY23Q/Q Change
Revenue
$1.7M
↓ 16.19%
Net Income
$-3.0M
↓ 73.03%
Net Profit Margin
-172.88%
↑ 364.41%
Q4 FY23Q/Q Change
Revenue
$2.7M
↑ 53.04%
Net Income
$-1.4M
↓ 52.21%
Net Profit Margin
-53.99%
↑ 118.89%
Q1 FY24Q/Q Change
Revenue
$1.8M
↓ 31.55%
Net Income
$-7.6M
↑ 430.4%
Net Profit Margin
-418.34%
↓ 364.35%
Q2 FY24Q/Q Change
Revenue
$2.2M
↑ 18.83%
Net Income
$-3.7M
↓ 51.59%
Net Profit Margin
-170.43%
↑ 247.91%
Q3 FY24Q/Q Change
Revenue
$1.9M
↓ 11.24%
Net Income
$-4.3M
↑ 15.81%
Net Profit Margin
-222.37%
↓ 51.94%
FY18Y/Y Change
Total Assets
$50.0M
↓ 5.86%
Total Liabilities
$30.0M
↓ 5.14%
FY19Y/Y Change
Total Assets
$86.0M
↑ 72.04%
Total Liabilities
$63.2M
↑ 110.54%
FY20Y/Y Change
Total Assets
$75.6M
↓ 12.07%
Total Liabilities
$35.5M
↓ 43.75%
FY21Y/Y Change
Total Assets
$92.0M
↑ 21.61%
Total Liabilities
$34.2M
↓ 3.71%
FY22Y/Y Change
Total Assets
$60.1M
↓ 34.67%
Total Liabilities
$35.1M
↑ 2.65%
FY23Y/Y Change
Total Assets
$45.2M
↓ 24.81%
Total Liabilities
$30.4M
↓ 13.41%
Q2 FY23Q/Q Change
Total Assets
$48.7M
↓ 16.61%
Total Liabilities
$43.2M
↑ 0.35%
Q3 FY23Q/Q Change
Total Assets
$54.7M
↑ 12.48%
Total Liabilities
$40.3M
↓ 6.57%
Q4 FY23Q/Q Change
Total Assets
$45.2M
↓ 17.43%
Total Liabilities
$30.4M
↓ 24.59%
Q1 FY24Q/Q Change
Total Assets
$36.2M
↓ 19.85%
Total Liabilities
$27.9M
↓ 8.17%
Q2 FY24Q/Q Change
Total Assets
$29.9M
↓ 17.58%
Total Liabilities
$24.8M
↓ 11.12%
Q3 FY24Q/Q Change
Total Assets
$24.1M
↓ 19.39%
Total Liabilities
$22.8M
↓ 7.93%
FY18Y/Y Change
Operating Cash Flow
$-19.8M
↑ 1370.59%
Investing Cash Flow
$4.5M
↓ 64.25%
Financing Cash Flow
$17.5M
↑ 38.48%
FY19Y/Y Change
Operating Cash Flow
$11.1M
↓ 156.21%
Investing Cash Flow
$-27.3M
↓ 702.25%
Financing Cash Flow
$19.5M
↑ 11.56%
FY20Y/Y Change
Operating Cash Flow
$-38.7M
↓ 448.65%
Investing Cash Flow
$9.4M
↓ 134.52%
Financing Cash Flow
$15.7M
↓ 19.7%
FY21Y/Y Change
Operating Cash Flow
$-37.3M
↓ 3.6%
Investing Cash Flow
$15.3M
↑ 62.33%
Financing Cash Flow
$50.5M
↑ 222.68%
FY22Y/Y Change
Operating Cash Flow
$-26.3M
↓ 29.57%
Investing Cash Flow
$19.8M
↑ 29.55%
Financing Cash Flow
$83.0K
↓ 99.84%
Q2 FY23Q/Q Change
Operating Cash Flow
$-9.3M
↑ 0.86%
Investing Cash Flow
$1.8M
↓ 137.39%
Financing Cash Flow
$-34.0K
↓ 100.34%

Durect Technicals Summary

Sell

Neutral

Buy

Durect is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Durect Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Durect Corp
-40.23%
-54.38%
30.46%
-92.13%
-95.9%
Neurocrine Biosciences Inc.
0.95%
-5.9%
3.78%
55.59%
17.86%
Haleon Plc Spon Ads
5.28%
15.21%
19.0%
31.85%
31.85%
Zoetis Inc.
1.85%
3.41%
-10.25%
-23.75%
40.1%
Viatris Inc.
-1.39%
22.71%
25.86%
1.59%
-21.97%
Catalent, Inc.
6.73%
12.99%
59.5%
-49.36%
19.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Durect Corp
NA
NA
-0.46
-0.5
-3.0
-0.4
NA
0.49
Neurocrine Biosciences Inc.
34.48
34.48
0.3
6.54
0.16
0.12
NA
26.87
Haleon Plc Spon Ads
28.44
28.44
1.72
0.34
0.07
0.04
0.02
1.82
Zoetis Inc.
33.15
33.15
2.48
5.88
0.47
0.15
0.01
11.59
Viatris Inc.
224.4
NA
0.08
2.67
-0.04
0.02
0.04
16.58
Catalent, Inc.
211.02
NA
518.67
0.2
-0.11
0.0
NA
19.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Durect Corp
Buy
$24.7M
-95.9%
NA
-187.84%
Neurocrine Biosciences Inc.
Buy
$13.1B
17.86%
34.48
17.21%
Haleon Plc Spon Ads
Buy
$43.7B
31.85%
28.44
10.75%
Zoetis Inc.
Buy
$79.7B
40.1%
33.15
26.55%
Viatris Inc.
Hold
$15.1B
-21.97%
224.4
-5.87%
Catalent, Inc.
Hold
$11.3B
19.07%
211.02
-9.34%

About Durect

durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use
Organization
Durect
Employees
48
CEO
Dr. James E. Brown D.V.M.
Industry
Health Technology

Management People of Durect

NameTitle
Dr. James E. Brown D.V.M.
Co-Founder, CEO, President & Director
Mr. Timothy M. Papp M.B.A.
CFO & Secretary
Dr. Norman L. Sussman M.D.
Chief Medical Officer
Ms. Judy R. Joice
Senior Vice President of Operations & Corporate Quality Assurance
Dr. WeiQi Lin M.D., Ph.D.
Executive VP of Research & Development and Principal Scientist
Ms. Jian Li M.B.A.
Senior VP of Finance, Corporate Controller & Secretary
Dr. Su Il Yum Ph.D.
Executive Officer

Important FAQs about investing in Durect from India :

What is Durect share price today?

Durect (DRRX) share price today is $0.77.

Can Indians buy Durect shares?

Yes, Indians can invest in the Durect (DRRX) from India.

With INDmoney, you can buy Durect at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Durect at zero transaction cost.

How can I buy Durect shares from India?

It is very easy to buy Durect from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Durect be purchased?

Yes, you can buy fractional shares of Durect with INDmoney app.

What are the documents required to start investing in Durect stocks?

To start investing in Durect, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Durect

Today’s highest price of Durect (DRRX) is $0.82.

Today’s lowest price of Durect (DRRX) is $0.77.

What is today's market capitalisation of Durect

Today's market capitalisation of Durect DRRX is 24.7M

What is the 52 Week High and Low Range of Durect

  • 52 Week High

    $1.88

  • 52 Week Low

    $0.48

How much percentage Durect is down from its 52 Week High?

Durect (DRRX) share price is $0.77. It is down by 59.04% from its 52 Week High price of $1.88.

How much percentage Durect is up from its 52 Week low?

Durect (DRRX) share price is $0.77. It is up by 60.08% from its 52 Week Low price of $0.48.

What are the historical returns of Durect?

  • 1 Month Returns

    -40.23%

  • 3 Months Returns

    -54.38%

  • 1 Year Returns

    30.46%

  • 5 Years Returns

    -95.9%

Who is the Chief Executive Officer (CEO) of Durect

Dr. James E. Brown D.V.M. is the current Chief Executive Officer (CEO) of Durect.